Nurse awarded medal by King for Gaza aid
A nurse in her 70s says she has no plans to stop working after winning an award from King Charles for her life-saving work in Gaza.
Chris Hunter travelled twice to Gaza as a volunteer to deliver frontline aid with UK-Med and described the mass casualties she dealt with as a "conveyor belt of carnage" amongst the backdrop of nearby explosions.
Ms Hunter, who lives in Grimsby and is a theatre nurse at Diana Princess of Wales Hospital, was presented with the Humanitarian Medal at Buckingham Palace.
"I know my family would prefer I just put my feet up and started knitting or something – but I'd far rather help stitch up patients who need our help in Gaza," she said.
The field hospitals where she worked in Al Mawasi and Deir El Balah, established with Foreign, Commonwealth & Development Office (FCDO) funding, have treated more than 300,000 patients as part of the UK Government's humanitarian response to the Israel/Gaza crisis.
Ms Hunter served with the Queen Alexandra's Royal Army Nursing Corps for 32 years which took her to places such as Bosnia, Kosovo, Iraq and Afghanistan.
She said she has "no plans to put her feet up" and is awaiting news from UK-Med regarding another deployment to Gaza or Ukraine.
Ms Hunter said: "I know I am elderly and aged, but I just feel as though I've got so much to offer.
"I have a lot of experience and skills which are best used supporting people who really need our help in Gaza.
"You are in that wooden box for a long time when you die, so I am trying to make the most of being fit and healthy."
Foreign Secretary David Lammy said: "This new medal recognises the incredible dedication and selfless service of individuals on the frontline of the UK's responses to some of the world's most devastating crises."
Listen to highlights from Lincolnshire on BBC Sounds, watch the latest episode of Look North or tell us about a story you think we should be covering here.
Medal recognises Gaza work as valuable, medic says
Nurse honoured with humanitarian medal from King
Deadly floods medic first to win new King's medal
UK-Med
Foreign, Commonwealth & Development Office
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Entrepreneur
4 hours ago
- Entrepreneur
Entrepreneur UK's London 100: apo
apo is democratising musculoskeletal (MSK) healthcare through its innovative and holistic AI-powered digital platform. Opinions expressed by Entrepreneur contributors are their own. You're reading Entrepreneur United Kingdom, an international franchise of Entrepreneur Media. Industry: Artificial Intelligence apo is democratising musculoskeletal (MSK) healthcare through its innovative and holistic AI-powered digital platform. In the UK alone, musculoskeletal (MSK) conditions affect over 20 million people each year, costing the NHS billions and resulting in more than 30 million lost working days annually. apo tackles this head-on with its comprehensive digital approach, organised around four core pillars (Move, Discover, Nourish, and Unwind) each tailored to empower users with personalised physical therapy, curated educational content, nutrition guidance, and mental health support. Founded in 2024 by Lauren Romanish, apo's mission is clear: transform how millions manage MSK pain, turning the industry's reliance on fragmented, episodic care into a seamless, continuous, and empowering user experience. Romanish has recently been named "The UK's Most Influential Female Founder in Healthcare to Watch." Furthermore, apo has received multiple awards and recognitions and is partnering with the National Health Service (NHS) to deliver more effective and efficient care — reducing our healthcare system's burdens and improving patient outcomes. Building Software as a Medical Device (SaMD), apo places safety, reliability, and clinical validation at the heart of its innovation. Unlike traditional healthcare apps, apo employs cutting-edge technology to deliver hyper personalised, interactive, and visually rich content. apo's intuitive design and real-time analytics encourage consistent user engagement, fostering long-term behavioural change. "apo's innovation lies in its ability to seamlessly blend clinical rigour with engaging, personalised wellness experiences. By putting sophisticated, adaptive AI directly into users' hands, we empower them not just to manage pain, but to fundamentally transform their relationship with health," says Romanish.
Entrepreneur
6 hours ago
- Entrepreneur
Entrepreneur UK's London 100: 32Co
Industry: Healthtech 32Co is a London based dental healthtech startup pioneering a new future for collaborative healthcare, by innovating a platform that enables generalist and specialist clinicians to work together and share knowledge, virtually, for the first time. The result? Improved quality of patient care, reduced costs, and new revenue streams. Less than ten years ago, 32Co's founder and CEO Dr Sonia Szamocki was still walking the halls of London's A&E departments. Treating dog bites, a dislocated shoulder, and a seizure could all be in a day's work. In London's hospitals, Dr Szamocki prized the ability to chat with and learn from colleagues with specialised knowledge, which she could then use to help patients with these problems: heart surgeons, facial clinic specialists, tendon specialists. However, she noticed that at a general level, access to the very best specialist treatment and knowledge was limited. Put plainly, an already small pool of specialist clinicians are unable to share their expertise with general clinicians. This made Dr Szamocki think, how could we help clinicians provide more cutting-edge treatment, sooner, and spread niche medical knowledge to help improve patient care? She soon pivoted to healthcare consulting at Boston Consulting Group, where she advised on major transformation projects. Later, under BCG's Digital Ventures arm, she helped build the world's largest digital health platform for haemophilia patients. Fast forward to 2022, Dr Szamocki founded 32Co. This company is a shining light for London-based startups - its platform and founder are fundamentally paving a new path that could revolutionise the way public and private healthcare systems operate in years to come. A testament to 32Co's vision, it has been backed by Balderton Capital, the early investors in Revolut, Depop, Wayve, and Clue. "As an A&E doctor, I witnessed firsthand the inefficiencies of the healthcare system - how specialist knowledge is siloed and how connecting patients with expert care is often slow and complex", says Dr. Szamocki. "I kept asking myself: why should healthcare innovation take decades to reach those who need it most? That's why I founded 32Co: to break down these barriers, empower clinicians to collaborate across specialties, and ensure every patient receives the best possible care, no matter where they are."
Entrepreneur
6 hours ago
- Entrepreneur
Entrepreneur UK's London 100: Amilis
Industry: Healthtech Sixth place on Entrepreneur UK's London100 list is Amilis. "We're not just helping women track their reproductive health," says Sarita Stefani, CEO of Amilis, "we're fixing a broken healthcare system by creating the dataset that's been missing all along. Amilis is the first platform to structure real-world data from both patients and doctors, finally giving women the care and answers they've always deserved." Amilis is an AI-powered doctor platform and patient app generating the first sex-specific real-world dataset in women's health, addressing a global problem: most healthcare data is still based on male physiology, leaving women undiagnosed, under-treated, and unheard. The company has been selected for the Plug and Play Health Accelerator, a global innovation platform and venture capital firm, and for Female Founders Rise, a community that empowers female and non-binary entrepreneurs with resources, coaching, and networking. They are currently raising their next round of funding and preparing to launch in Europe in 2025. What sets Amilis apart is that they don't just digitise care — they generate high-value, sex-specific data that life sciences companies desperately need to design better drugs, run more inclusive clinical trials, and finally close the gender data gap in medicine.
